Xenetic Biosciences, Inc.
XBIO
Last
$2.19
Day
+3.3%
1y
-77.6%
5y
-90.7%
52w
-79.3%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1132d
EMA 21
2.59
EMA 50
2.93
EMA 200
3.01
20d high
-51.0%
5y high
-91.2%
5y range
1th
Positions held
Your positionsXBIO isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$2.47
Stop
$1.83
Stop distance
16.4%
Target vs last
+12.8%
Fundamentals
| Market cap | $4.97M | Enterprise value | -$1.50M | Trailing P/E | — | Forward P/E | -3.21 |
| PEG | — | Price / book | 0.66 | Beta | 2.20 | Dividend yield | 0.00% |
| Revenue growth | 12.0% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -147.1% |
| Profit margin | -75.9% | ROE | -47.0% | ROA | -26.8% | Debt / equity | — |
| Current ratio | 7.44 | Free cash flow | -$1.17M | Analyst recommendation | none | Mean target | — |
| 52w high | $8.87 | 52w low | $1.87 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.7M | $0.8M | $0.8M | $1.0M | $0.6M | — |
| Op margin | -147.1% | -62.2% | -81.3% | -53.0% | -122.8% | — |
| Net income | -$0.9M | -$0.5M | -$0.6M | -$0.5M | -$0.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.0M | -$0.5M | -$0.6M | -$0.5M | -$0.7M | — |
- Revenue -18% vs prior quarter ($0.7M vs $0.8M).
- Operating margin compressed to -147.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | — |
| Op margin | -95.2% | -168.2% | -177.8% | -393.6% | — |
| Net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$2.8M | -$4.2M | -$4.5M | -$6.7M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-16 · Top Midday Decliners
2026-09-16 · Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake
2026-09-16 · Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
2026-08-07 · Xenetic Biosciences: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patternsXBIO · daily-17.5% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin